Development↦Management↦Informed Consent Process↦Procedures
What is it? Why is it important?
The Informed Consent Process (ICP) describes how persons or hospital patients are recruited for study participation.
Key steps include to:
- Assess the person`s/patient’s eligibility (i.e. compliance with study inclusion & exclusion criteria)
- Hand out the Participant Information Sheet
- Explain and ensure persons/patients understand:
- Their rights (e.g. right to information, right to withdraw from the study)
- The conduct of the study (e.g. research question, study design)
- Safety issues (e.g. participant risk-benefit)
- Requirements (e.g. time investment, providing health-related personal data and biological material)
- Potential additional consent (e.g. further-use of leftover biological material)
Once the person/patient has agreed to study participation:
- Both the participant and Site-INV sign and date the Informed Consent Form (ICF)
- The ICF is filed in the Investigator Site File ISF
- The participant receives a signed copy of the ICF
- Study inclusion is documented in the patient file and the study database
More
The implementation of an ICP can face increasing challenges due to:
- The target population of the study (e.g. healthy volunteers, pregnant women, children, adolescents, persons unable to give consent)
- The complexity of the study (e.g. placebo controlled studies, emergency situations, inclusion of legal representatives)
- Increased study risks (e.g. first in man, intervention with novel drugs lacking extensive safety profiles, vulnerable target population)
- The collection of biological material and health related persona data for further-use projects
In the event of a substantial amendment during study conduct, participants should:
- Be informed about the changes including potential consequences (e.g. additional safety concerns, sampling of biological material, visits, data collection, and time investments)
- Re-consent to amended study procedures by dating and signing an updated ICF, approved by the Ethics Committee (EC)
What do I need to do?
As a SP-INV, describe ICP procedures in an SOP/WI or in the study protocol.
Aspects to consider include:
- Means on how to inform and obtain consent (e.g. in writing and/or orally, exemption from the written form)
- The timing of consent (e.g. with study procedures planned the same day, or post-hoc in emergency situations, incomplete information, step-wise consent)
- Special provisions (e.g. language barriers, children as target population)
- How to document consent (e.g. in patient file, study database)
To ensure ICPs are correctly implemented during study conduct:
- Train study staff on ICPs, including potential changes
- Ensure study staff authorized to carry out ICPs are defined in a delegation-log
- Ensure persons/patients have the opportunity to ask questions, and are given adequate time to decide on study participation
- Ensure only Ethics Committee (EC) approved documents (ICF, PIS) are used (e.g. document management)
- Define how to document ICP deviations (e.g. note to file)
More
For the ICP additional aspects may include:
- The use of advertisement
- Participant remuneration
- Handling of data and biological material from participants who withdrew from the study, or were lost to follow-up
- Re-consent during study conduct (i.e. due to a protocol amendment potentially affecting participant willingness to remain in the study)
All these aspects must be discussed and submitted to the Ethics Committee (EC) for approval
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissethics – see in particular:
- Checklist for the recruitment of study participants by means of advertising
- Specimen text for advertisement
- Guidelines on the retention period of biological material and personal data of further-use projects without consent
- Conception and application of an electronic informed consent
- Time for consideration
- Monetary contributions to patients participating in research projects
References
ICH GCP E6(R3) – see in particular guideline
- II. Principles of ICH GCP Nr. 2 Informed consent
- 2.8. Informed consent of trial participants
- Appendix C.3 Essentiality of Trial Records
Declaration of Helsinki – see in particular principles
- 25 – 32 Free and Informed Consent
ISO 14155:2020 Medical devices (access liable to costs) - see in particular sections
- 5.8 Informed consent
Swiss Law
HRA – see in particular articles and chapters
- Art. 3f Definition health-related personal data
- Art. 16 Informed consent
- Art. 17 Consent to further use for research
- Art. 18 Incomplete information
- Chapter 3, section 1. Research involving children, adolescents, adults lacking capacity.
- Chapter 3, section 2. Research involving pregnant women, IFV embryos, foetuses
- Chapter 3, section 3. Research involving prisoners
- Chapter 3, section 4. Research in emergency situation
ClinO – see in particular articles
- Art. 7 Information
- Art. 8 Exception to written form
- Art. 9 Consequences of revocation of consent
- Art. 15 Post hoc consent in emergency situations
ClinO-MD – see in particular articles
- Art. 3b Participant information, consent
- Art. 3d Emergency situations
HRO – see in particular articles and chapter
- Art. 8 Informed Consent
- Art. 9 Exception to written form
- Art. 10 Consequences of revocation of consent
- Art.11 Research projects in emergency situations
- Art. 41 Research involving deceased persons
- Art. 44 Informed consent involving embryos and foetuses
- Chapter 3, section 2. Informed consent for and information on further use of biological material and health-related data